SP 0173

Drug Profile

SP 0173

Alternative Names: Diphtheria/Pertusis/Tetnus vaccine - Sanofi Pasteur; DTaP vaccine - Sanofi Pasteur; SP0173; Tdap vaccine - Sanofi Pasteur

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 22 Feb 2017 Sanofi completes a phase I/II trial in Pertussis, Diphtheria and Tetanus (Prevention) in USA (IM) (NCT02587520)
  • 01 Oct 2015 Phase-I/II clinical trials in Diphtheria (Prevention) in USA (IM)
  • 01 Oct 2015 Phase-I/II clinical trials in Pertussis (Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top